Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

NEUROCUPLE™ como alternativa a los opioides tras la artroplastia total de rodilla

10 de noviembre de 2026 actualizado por: Jacques E. Chelly

El papel de NEUROCUPLE™ como alternativa a los opioides en pacientes tras artroplastia total de rodilla

The goal of this clinical trial is to learn if the NEUROCUPLE device can reduce pain and opioid use after primary unilateral total knee arthroplasty (TKA) in adults.

The main questions it aims to answer are:

  • Does the NEUROCUPLE device reduce postoperative pain at rest during the first 24 hours after TKA?
  • Does the NEUROCUPLE device reduce opioid consumption during the first 24 hours after TKA?

Researchers will compare the NEUROCUPLE device to a placebo device (identical in appearance but inactive) to see if the device reduces pain and opioid use after surgery.

Participants will:

  • Apply the NEUROCUPLE device or placebo device for 7 days following surgery
  • Have their pain and opioid use monitored through clinical records and patient reporting
  • Report pain at rest and during movement on postoperative Days 2 and 7
  • Be assessed for nausea, vomiting, device-related side effects, length of hospital stay, and overall satisfaction

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

274

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Jacques E. Chelly, MD, PhD, MBA
  • Número de teléfono: (412)623-6904
  • Correo electrónico: ChelJE@anes.upmc.edu

Copia de seguridad de contactos de estudio

  • Nombre: Heather Margonari, DNP, FNP, BC
  • Número de teléfono: 412-623-1914
  • Correo electrónico: margonarih@upmc.edu

Ubicaciones de estudio

    • Pennsylvania
      • Pittsburgh, Pennsylvania, Estados Unidos, 15232
        • UPMC Shadyside Hospital
        • Investigador principal:
          • Jacques E. Chelly, MD, PhD, MBA
        • Contacto:
          • Heather Margonari,, DNP, FNP-BC
          • Número de teléfono: 412-623-1914
          • Correo electrónico: margonarih@upmc.edu
        • Contacto:
      • Pittsburgh, Pennsylvania, Estados Unidos, 15237
        • UPMC Passavant Hospital
        • Investigador principal:
          • Jacques E. Chelly, MD, PhD, MBA
      • Pittsburgh, Pennsylvania, Estados Unidos, 15146
        • UPMC East Hospital
        • Investigador principal:
          • Jacques E. Chelly, MD, PhD, MBA

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • >18 years of age
  • Scheduled for elective primary unilateral TKA

Exclusion Criteria:

  • Children (<18 yr.)
  • Pregnant women
  • Active alcoholism (defined as daily use of more than 1 liter of wine and /or 3 or more shots of hard liquor) or drug abuse (defined as daily use of illicit drugs)
  • Severe chronic pain condition that requires daily preoperative opioid dependence
  • Other concomitant surgery being performed in addition to TKA
  • Patients undergoing bilateral TKA
  • Patients undergoing knee replacement revision
  • Patients with limited mobility (in a wheelchair or requiring a walker)
  • Patients who are not returning home after surgery

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: NEUROCUPLE™ Group

This arm of subjects will receive the active NEUROCUPLE™ patch to wear for 7 days following their TKA surgery.

nCAP Medical has developed an effective, safe, non-opioid alternative, the NEUROCUPLE™ device, based on an innovative nanotechnology to reduce surgical pain and facilitate functional recovery while reducing opioid prescriptions, opioid-related adverse events and reducing the cost of care in millions of Americans undergoing TKA each year. The patch will be worn for 7-days

Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications

Comparador falso: Sham Group

This arm of subjects will receive the placebo (non-active, sham) patch to wear for 7 days following their TKA surgery.

Participants in both arms will receive approved Enhanced Recovery After Surgery (ERAS) multimodal care, including preoperative education and optimization, intraoperative minimally invasive techniques and multimodal analgesia, and postoperative early mobilization, early nutrition, pain control, and monitoring for complications

Non-active placebo patch visually identical to NEUROCUPLE™ worn for 7 days following total knee arthroplasty.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Opioid Consumption
Periodo de tiempo: 0- 24 hours post-surgery

Total opioid consumption, expressed in milligrams of morphine equivalents (MME), during the first 24 hours following surgery.

Opioid use will be calculated using all available data sources, including in-hospital medication administration records and, when applicable, the state Prescription Drug Monitoring Program (PDMP).

MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, while higher MME values suggest increased opioid use and potentially greater pain or slower recovery.

0- 24 hours post-surgery
Pain at Rest Using Numerical Rating Scale (NRS)
Periodo de tiempo: 0-24 hours post-surgery

Pain at rest during the first 24 hours after surgery will be assessed using a Numerical Rating Scale (NRS; 0 = no pain, 10 = worst pain) and compared between the NEUROCUPLE™ patch group and the placebo patch group. Higher scores indicate worse pain

0-24 hours post-surgery

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Pain Scores Using Numerical Rating Scale (NRS) at Rest and during Movement
Periodo de tiempo: Post-operative at Day 2 and Day 7

Pain will be assessed using a Numerical Rating Scale (0 = no pain, 10 = worst pain) at rest and during movement on postoperative Days 2 and 7. Higher scores indicate worse pain.

Post-operative at Day 2 and Day 7
Patient Satisfaction
Periodo de tiempo: at Post-operative Day 7

Patient satisfaction with recovery and device use will be assessed on postoperative Day 7 using standardized questionnaires. Scores range from 0 to 10, where 0 indicates the lowest level of satisfaction and 10 indicates the highest.

at Post-operative Day 7
Opioid Consumption
Periodo de tiempo: Post-Operative Day 0- Day 7

Total opioid consumption, expressed in milligrams of morphine equivalents (MME), will be recorded over the 7-day postoperative period.

Opioid use will be calculated using all available data sources, including in-hospital medication administration records and the state Prescription Drug Monitoring Program (PDMP) when applicable.

MME values will be compared between the NEUROCUPLE™ patch group and the placebo patch group. Lower MME values indicate reduced opioid requirements and may reflect improved postoperative pain control, whereas higher MME values suggest increased opioid use and potentially greater pain or slower recovery.

Post-Operative Day 0- Day 7
Postoperative Adverse Events and Device-Related Side Effects
Periodo de tiempo: Postoperative Days 0-7

The incidence of postoperative adverse events, including any events determined to be related to the study device, will be recorded and compared between the treatment groups during the 7-day postoperative period.

Lower incidence rates indicate fewer complications and a more favorable safety profile, whereas higher incidence rates suggest increased complications, potential device-related issues, or a less favorable safety profile.

Postoperative Days 0-7
Incidence of postoperative nausea and/or vomiting (yes/no)
Periodo de tiempo: Postoperative Days 0-7

Incidence and severity of postoperative nausea and vomiting will be recorded over the 7-day postoperative period as (yes/no) and compared between groups.

Postoperative Days 0-7
Postoperative Length of Stay
Periodo de tiempo: From the date of surgery until hospital discharge (within the 7-day study period)

Length of hospital stay, defined as the number of days from the date of surgery to the date of hospital discharge, will be recorded and compared between groups.

Lower length of stay values indicate faster recovery, fewer complications, and earlier readiness for discharge. Higher length of stay values suggest slower recovery, increased complications, or higher postoperative symptom burden.

From the date of surgery until hospital discharge (within the 7-day study period)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Jacques E. Chelly, MD, PhD, MBA, University of Pittsburgh / UPMC
  • Director de estudio: Alisha Maslanka, BS, CCRC, University of Pittsburgh / UPMC
  • Director de estudio: Heather Margonari,, University of Pittsburgh / UPMC

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

1 de diciembre de 2026

Finalización primaria (Estimado)

1 de agosto de 2027

Finalización del estudio (Estimado)

1 de noviembre de 2027

Fechas de registro del estudio

Enviado por primera vez

23 de febrero de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de febrero de 2026

Publicado por primera vez (Actual)

27 de febrero de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

12 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

Sí

producto fabricado y exportado desde los EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir